SFA THERAPEUTICS NEWS ARCHIVES

EXPLORE OUR EXTENSIVE LIBRARY OF NEWS RELEASES

Jan 5, 2025

New Scientific Discoveries Yield Impressive Real-World Applications

A New, More Natural Approach to Drug Discovery

Sep 16, 2024

A Vision to Heal the World with Ira Spector

Conversations Life Science Leaders are not Having

Sep 18, 2024

A Better Response to Inflammation: Q&A with Dr. Ira Spector

Spector Discusses his Company’s Goal of Fighting Inflammation without Hurting the Immune System.

Jul 16, 2024

SFA Therapeutics Strengthens Management Team with Appointment of Chief Operating Officer

SFA Therapeutics Recruits New COO

Sep 4, 2024

SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics

SFA Therapeutics Boosts Management Team

May 30, 2024

SFA Therapeutics Announces Completion of Enrollment in Phase 1b Trial of SFA-002 for Psoriasis

Phase 1b Trial of SFA-002 for Psoriasis Update

Oct 22, 2024

SFA Therapeutics Strengthens Intellectual Property in Autoimmune Disease and Hepatocellular Carcinoma

Autoimmune Disease and Hepatocellular Carcinoma

May 17, 2024

The Promise of Therapeutics from Molecules Within Our Body

Senior Leaders at SFA Therapeutics Emphasize the Importance of Re-establishing Homeostasis in Drug Development Approaches.

May 16, 2024

SFA Therapeutics Strengthens Management Team with Appointment of Chief Medical Officer

Stefan C. Weiss, MD, MBA, Joins SFA Therapeutics as Chief Medical Officer.

Feb 29, 2024

Ben Franklin Healthcare Investments Invests $1.3 Million in Four Companies

Ben Franklin Healthcare Investments Continues Support of SFA Therapeutics with Additional Investment.

Dec 7, 2023

SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent

Clinical Results, Bridge Financing, and Patent News

Aug 14, 2023

SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis

Results for Mild-to-Moderate Chronic Plaque Psoriasis

Jul 12, 2023

SFA Therapeutics Founders Publish an Article Titled “Short‑chain Fatty Acids in Cancer Pathogenesis”

SFAs in Cancer Pathogenesis

Apr 2, 2023

Developing the Next Big Thing

The Journey of a CEO: Navigating the Differences Between a Global Company & A Startup

Jan 27, 2023

A Biotech CEO’s Favorite ‘F’ Word

At SFA Therapeutics, Patients are the “Focus” of Ira Spector’s Approach to Changing the Course of Autoimmune Disease.

Jan 22, 2023

SFA Therapeutics Announces FDA Clearance for Amendment to Extend Phase 1b Trial of SFA-002 for Psoriasis

SFA Therapeutics Received Clearance from the U.S. Food and Drug Administration (FDA) to Proceed with an Extension to the Ongoing Phase 1b Clinical Trial of SFA-002

Dec 24, 2022

SFA Therapeutics Will Begin Testing of SFA001 in a Phase 1 Exploratory Trial at Einstein Hospital in Philadelphia 1Q 2023

Dr Manisha Verma MD, MPH to Act as Principal Investigator

Dec 24, 2022

Tales From the 2022 Biotech VC Fundraising Trail

After the Bonanza of 2021, Life-Sciences Entrepreneurs Reset Their Expectations as Financing Contracted

Dec 4, 2022

Biotech Showcase: The Investor Conference for Innovators

SFA Therapeutics Will be Presenting a Corporate Update at the Biotech Showcase

Sep 20, 2022

SFA Publishes New Approach to Treating Hepatitis B and Chronic Liver Disease, with the Goal of Developing a Functional Cure

Patients who are carriers of the hepatitis B virus (HBV) are at high risk of chronic liver disease (CLD)

Jun 20, 2022

SFA Therapeutics, Inc. Closes Seed Round Raise of $4M

Funds are Focused on Phase 1b Clinical Trial in Psoriasis

Jan 6, 2022

Pismo Ventures' National Venture Plan Startup Competition Announces Winners

National Event Provided Startup Businesses Unprecedented Access to Venture and Investment Industry Experts for the Second Year in a Row

Oct 15, 2021

SFA Therapeutics Ranked Most Fundable Company by Pepperdine Graziadio Business School

SFA Therapeutics Named Among the Most Fundable Winners 2021

Jul 12, 2021

These Philly Startups were Accepted into Y Combinator’s Summer 2021 Cohort

The Companies are Focused in the Therapeutics and B2B SaaS Space

May 24, 2021

SFA Therapeutics Selected as 2021 Company and Pitch Presentation Award Honoree at 11th Annual BioPartnering Conference

"On Behalf of the Millions of Patients Who Suffer from Autoimmune Diseases, we are Delighted that Our Work is Beginning to Gain Recognition”

May 21, 2021

Announcing BioNJ's BioPartnering Company & Pitch Presentation Award Honorees

BioNJ Announced the Winners of its 2021 Company and Pitch Presentation Competition

Nov 16, 2020

Houston Organization Names 10 Most Promising Life Sciences Startups

Ones to Watch

Oct 13, 2020

SFA Therapeutics Invited to Present at Angel Venture Fair

Investors Meet Thirty of Top Startups in America

Jun 29, 2020

SFA Therapeutics Announces FDA Approval to Begin IND Trial

Clinical Trial Examines Human Microbiome-based Drug SFA002 In Mild to Moderate Plaque Psoriasis

Jun 24, 2020

Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19

SFA Therapeutics Receives Award from Ben Franklin Technology Partners. Melior Discovery Selected as Partner.

May 18, 2020

Endless Frontier Labs at New York University’s Stern School of Business Graduates its 2019-2020 Cohort of Startups

Endless Frontier Labs Startups

Apr 8, 2020

SFA Therapeutics, Inc. Announces Start of Phase 1b Clinical Trial in the Treatment of Mild-to-Moderate Plaque Psoriasis

Clinical-Stage Biotechnology Company Announces the Start of First Clinical Trial for the Treatment of Psoriasis

Oct 28, 2019

SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)

FDA Grants Orphan Drug Designation (ODD) to SFA001

Oct 25, 2019

SFA Therapeutics, Inc. to Present at the Microbiome R&D and Business Collaboration Forum

Will Report on Clinical Development Plans for Multiple Promising Therapeutics Derived from Human Microbiome

Dec 5, 2018

SFA Therapeutics Wins U.S. Patent for Use of Short Chain Fatty Acids in Cancer Prevention

SFA Therapeutics receives key patent for treatment for hepatitis B to prevent progression to hepatocellular carcinoma (HCC)

Sep 27, 2019

Inside the Patient Entrepreneur’s Mind: Ira Spector, PhD

An Interview with Dr. Ira Spector

Sep 9, 2019

Innovations in Dermatological Sciences

Agenda for the Innovations in Dermatological Sciences at Rutgers University

Aug 5, 2019

SFA Therapeutics, Inc. Requests FDA Orphan Drug Designation (ODD) for SFA001 for Treatment of Hepatocellular Carcinoma (HCC)

SFA Therapeutics Files with FDA for Orphan Drug Designation for SFA001

May 31, 2019

SFA Therapeutics to Present Human Psoriasis Data for Microbiome-based Drug (SFA002) at the Global Biotech Entrepreneur Forum and the BIO International Convention

Also Presenting Preclinical Data on Two Additional Pipeline Products

Dec 22, 2017

The 10 Most Promising Biotech Startups in the United States

SFA Therapeutics Listed in the Top 10

Jan 22, 2018

CEO Leadership Series: Ira C. Spector, Ph.D., CEO, SFA Therapeutics

How Non-Traditional Thinking Led to Optimized Processes and Career Advancement

Aug 23, 2018

And the 2018 Stellar StartUps Finalists are …

SFA Therapeutics Makes the Finalists

Dec 5, 2018

SFA Therapeutics Wins U.S. Patent for Use of Short Chain Fatty Acids in Cancer Prevention

New Treatment for Hepatitis B - SFA Therapeutics Receives Key Patent for Treatment for Hepatitis B to Prevent Progression to Hepatocellular Carcinoma (HCC)

Mar 2, 2019

Helsinn Investment Fund: 10 Finalists for Lyfebulb-Helsinn Innovation Summit & Awards in Oncology

Ten Finalists Have Been Chosen for the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology. The Award Recognizes Patient Entrepreneurs’ Innovations for Cancer and Cancer Supportive Care Using Therapeutics, Diagnostics, Medical Devices or Healthcare IT Tools

Mar 19, 2019

SFA Therapeutics Wins Second Key U.S. Patent for Treatment of Chronic Liver Diseases

New Drug to Treat Liver Cancer is Patented